Drugs & Targets FDA issues CRL for rivoceranib + camrelizumab as a first-line treatment for unresectable or metastatic HCC July 17, 2026Vol.52 No.28
Drugs & Targets European Commission grants marketing authorization for Tepkinly + R2 in R/R FL July 10, 2026Vol.52 No.27
Drugs & Targets FDA approved 17 new cancer treatments in 2025, OCE annual report states July 02, 2026Vol.52 No.26
Drugs & Targets FDA approves expanded use of Casgevy for pediatric sickle cell disease or transfusion-dependent beta thalassemia July 02, 2026Vol.52 No.26
Drugs & Targets EC approves Padcev + Keytruda as perioperative treatment option for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer June 26, 2026Vol.52 No.25
